FDA approval of IHEEZO (chloroprocaine hydrochloride oOphthalmic gel) 3% for ocular surface anesthesia
Harrow Health , an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, and Sintetica, S.A., a growing pharmaceutical company focused on analgesics, local anesthetics, and sterile injectable solutions, jointly announced the FDA approval of IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% for ocular surface anesthesia